AI could help doctors make better liver cancer decisions

NCT ID NCT07538882

Recruiting now Diagnosis Sponsor: Beijing Tsinghua Chang Gung Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an artificial intelligence (AI) model can help doctors more accurately stage and choose treatments for liver cancer (hepatocellular carcinoma). About 108 patients and doctors from different hospitals will participate. Doctors will make decisions with and without AI help to see if the AI improves accuracy and reduces differences between large and small hospitals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Artificial intelligence (AI) model for staging and treatment decisions
What this could lead to: If successful, this could show that AI helps doctors make more accurate liver cancer staging and treatment decisions, reducing differences in care between large and small hospitals.
What could go wrong: This is a small, early-stage study (108 participants) testing a tool, not a treatment. The AI may not improve accuracy in real-world settings, and results may not apply to all hospitals or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, Changping, 102218, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.